Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956388 | 0.89 | CYP4F2 (0.48) | CYP4F2CYP4A11KMT2AALDH1A1TAAR1 | |
| SCHEMBL1151562 | 0.88 | CYP4F2 (0.69) | CYP4F2CYP4A11KMT2AALDH1A1TAAR1 | |
| SCHEMBL12602245 | 0.85 | CYP4F2 (0.56) | CYP4F2CYP4A11KMT2AALDH1A1GAA | |
| SCHEMBL15334186 | 0.85 | L3MBTL1 (0.52) | CYP4F2CYP4A11KMT2AALDH1A1TAAR1 | |
| SCHEMBL956095 | 0.82 | CYP4F2 (0.54) | CYP4F2CYP4A11ALDH1A1TAAR1LMNA | |
| SCHEMBL957050 | 0.82 | CYP4F2 (0.54) | CYP4F2CYP4A11KMT2AALDH1A1TAAR1 | |
| SCHEMBL1511092 | 0.82 | CYP4F2 (0.64) | CYP4F2CYP4A11KMT2AALDH1A1TAAR1 | |
| SCHEMBL28873178 | 0.81 | CYP4F2 (0.52) | CYP4F2CYP4A11KMT2AALDH1A1MEN1 | |
| SCHEMBL7331602 | 0.79 | TAAR1 (0.56) | KMT2AALDH1A1TAAR1MEN1 | |
| SCHEMBL717900 | 0.78 | TDP1 (0.56) | CYP4F2CYP4A11ALDH1A1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101959889-A | Heterocyclic compounds as inhibitors of CXCR2 | NOVARTIS AG | 2011-01-26 | — | — | CN | disclosed |
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2257552-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009106539-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR3 | CYP4F2 1678/4885CYP4A11 1251/4885KMT2A 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.